Premium
Ranolazine—Treatment of Ventricular Tachycardia and Symptomatic Ventricular Premature Beats in Ischemic Cardiomyopathy
Author(s) -
NANDA SUDIP,
LEVIN VADIM,
MARTINEZ MATTHEW W.,
FREUDENBERGER RONALD
Publication year - 2010
Publication title -
pacing and clinical electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 101
eISSN - 1540-8159
pISSN - 0147-8389
DOI - 10.1111/j.1540-8159.2010.02733.x
Subject(s) - ranolazine , medicine , cardiology , ventricular tachycardia , ischemic cardiomyopathy , cardiomyopathy , radiofrequency ablation , angina , ablation , anesthesia , heart failure , ejection fraction , myocardial infarction
Premature ventricular complexes (PVCs) are a frequent occurrence in the presence of ischemic heart disease. A very high PVC load can be symptomatic or occasionally result in a cardiomyopathy (CMP). Treatment options include pharmacologic agents and radiofrequency ablation (RFA). RFA has been successful in treating PVCs in symptomatic patients or in the presence of unexplained CMP. Ranolazine is a piperazine derivative used for treating chronic stable angina. It also has antiarrhythmic properties. We report a patient with ischemic CMP, symptomatic PVCs, and monomorphic ventricular tachycardia (VT) despite attempts to control symptoms with two antiarrhythmic drugs. Initiation of ranolazine led to marked reduction in PVCs along with control of VT and symptoms. (PACE 2010; 33:e119–e120)